A common side effect of stress and trauma in critically ill patients is a rapid increase in blood glucose levels. As with diabetes, the levels can be reduced and controlled by the infusion of insulin. But glucose levels peak and change much more quickly in the ICU environment and there is little room for trial and error. If the situation is not normalised, then complications and even deaths can and do occur.
Twice in the past, Europe-wide studies and trials were put in place to try and come up with a solution to the problem. But in both cases they were prematurely halted because researchers could not solve the problem of overcompensating and patients developing hypoglycaemia, or abnormally low blood sugar levels.
“What these studies did clearly indicate is that the establishment of normal glucose levels in critically ill patients is very difficult to achieve without some sort of automated system to help the nurses,” says Dr Martin Ellmerer, scientific coordinator of the CLINICIP project which has developed just such a system.Nurses’ no-nonsense approach
Partners in this EU-funded project, academic medical institutions plus one private-sector medical equipment manufacturer, decided they needed to develop a two-step approach. “We first developed a decision-support system which met all the criteria outlined by the ICU staff, and later developed a fully automated system,” he tells ICT Results.
At the heart of both systems is a sophisticated bit of computer software (an algorithm) written especially for this project.
With the decision-support system, nurses still have to draw blood from patients in the traditional way and test it for glucose levels. They enter the information via the user interface – a touch screen – the researchers have developed. The algorithm takes over at this stage, calculates how much insulin is needed and automatically administers it. It also alerts the nurse when a new blood sample needs to be taken and analysed – half an hour in the worst cases and up to four hours in less severe cases.
“We have fully functioning prototypes of the decision-support system which we successfully trialled in ICUs at different hospitals around Europe,” Ellmerer says. The project’s industrial partner, B. Braun Melsungen AG, is ready to go into commercial production of the system working together with the clinical partners.
“We will first have to go through an approval process and the systems should be commercially available to hospitals in mid-2009,” Ellmerer says. B. Braun is one of the leading manufacturers of infusion systems used in hospitals, and the CLINICIP technology will be incorporated into these as it was during the trials.Developing the real deal
The drawback of this is that a dedicated needle is necessary. “Unfortunately, this is unavoidable for a fully automated system,” Ellmerer points out. Using fibre-optic technology the needle draws blood, sends it for analysis and then returns it to the patient’s vein as well as administering the necessary dose of insulin.
“We have performed a proof-of-concept study to show we are able to establish glucose control in a clinical setting,” Ellmerer says.
To develop the sensor technology further and then commercialise it, a spin-off company will be set up with Ellmerer as CEO and one of the shareholders. The other shareholders are individuals from project partners in CLINICIP. The spin-off will work closely with B. Braun and the partners, although they are not stakeholders in it.
Ellmerer expects the fully automated two-step system to be commercially available in 2011.
“Our research and the products which result from it should have a pretty fundamental impact on ICUs,” he says. “They should improve survival chances, reduce complications, such as sepsis and organ failure, and reduce the time patients need to spend in ICUs.”
Ahmed ElAmin | alfa
Construction of practical quantum computers radically simplified
05.12.2016 | University of Sussex
UT professor develops algorithm to improve online mapping of disaster areas
29.11.2016 | University of Tennessee at Knoxville
In recent years, lasers with ultrashort pulses (USP) down to the femtosecond range have become established on an industrial scale. They could advance some applications with the much-lauded “cold ablation” – if that meant they would then achieve more throughput. A new generation of process engineering that will address this issue in particular will be discussed at the “4th UKP Workshop – Ultrafast Laser Technology” in April 2017.
Even back in the 1990s, scientists were comparing materials processing with nanosecond, picosecond and femtosesecond pulses. The result was surprising:...
Have you ever wondered how you see the world? Vision is about photons of light, which are packets of energy, interacting with the atoms or molecules in what...
A multi-institutional research collaboration has created a novel approach for fabricating three-dimensional micro-optics through the shape-defined formation of porous silicon (PSi), with broad impacts in integrated optoelectronics, imaging, and photovoltaics.
Working with colleagues at Stanford and The Dow Chemical Company, researchers at the University of Illinois at Urbana-Champaign fabricated 3-D birefringent...
In experiments with magnetic atoms conducted at extremely low temperatures, scientists have demonstrated a unique phase of matter: The atoms form a new type of quantum liquid or quantum droplet state. These so called quantum droplets may preserve their form in absence of external confinement because of quantum effects. The joint team of experimental physicists from Innsbruck and theoretical physicists from Hannover report on their findings in the journal Physical Review X.
“Our Quantum droplets are in the gas phase but they still drop like a rock,” explains experimental physicist Francesca Ferlaino when talking about the...
The Max Planck Institute for Physics (MPP) is opening up a new research field. A workshop from November 21 - 22, 2016 will mark the start of activities for an innovative axion experiment. Axions are still only purely hypothetical particles. Their detection could solve two fundamental problems in particle physics: What dark matter consists of and why it has not yet been possible to directly observe a CP violation for the strong interaction.
The “MADMAX” project is the MPP’s commitment to axion research. Axions are so far only a theoretical prediction and are difficult to detect: on the one hand,...
16.11.2016 | Event News
01.11.2016 | Event News
14.10.2016 | Event News
08.12.2016 | Life Sciences
08.12.2016 | Physics and Astronomy
08.12.2016 | Materials Sciences